Citigroup Upgrades Dr Reddy's Laboratories to Buy, Raises Price Target to $1450
Citigroup analyst Vivek Agrawal upgrades Dr Reddy's Laboratories (NYSE:RDY) from Sell to Buy and raises the price target from $1040 to $1450.
Share
Why It Matters
A big bank analyst now thinks Dr Reddy's is a good buy. They raised their target price because they see better chances ahead.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.